BioServe Unveils New DNA Methylation Service


LAUREL, MD -- (MARKET WIRE) -- December 11, 2006 -- BioServe Biotechnologies, a leader for fast, economical processing and analyses of genomic content from biological samples, today introduced its new DNA Methylation Analysis Service using Sequenom, Inc.'s (NASDAQ: SQNM) MassARRAY® System and EpiTYPER™ methodology. DNA methylation markers are a new and important class of biomarkers that are significant because of their correlation to gene activity. High levels of cytosine methylation in genomic regions (CpG islands) are often associated with decreased or completely inhibited gene expression. Researchers now believe that DNA methylation patterns play an important role in early cancer detection and prognosis. BioServe's Methylation Analysis Service will aid researchers' understanding of methylation patterns with quantitative results in the form of methylation ratios in targeted genomic regions.

"DNA methylation patterns affect phenotype and cell biology, as most obviously seen in cancers. Understanding this epigenetic dysregulation is essential to potentially mediating many common diseases. BioServe's new Methylation Analysis Service will help researchers studying a variety of diseases, identify CpG disturbances in the genome and gain new insights into the roots of disease," said Rama Modali, President of BioServe. "For example, our Methylation Service gives researchers the ability to efficiently measure methylation activity at individual sites in the genome and quantitatively measure methylation ratios across multiple methylation sites over multiple samples."

About BioServe

BioServe delivers a complete 'biomaterial to validated data' genomics solution. BioServe's fast, economical processing and analyses of genomic content from biological samples helps researchers worldwide to gain the pre-clinical genomic results required to achieve breakthroughs in research, drug discovery and molecular diagnostics. BioServe's technology, products and services form the foundation for optimal pre-clinical workflows spanning innovative methodologies for processing nucleic acids, DNA synthesis, high throughput sequencing and genotyping, genome wide-scans and gene expression analyses. BioServe's customers include leading pharmaceutical and biotechnology companies, and government and academic research institutions. BioServe has headquarters in Laurel, MD and Hyderabad, India. For more information please visit www.bioserve.com or call 301-470-3362.

Sequenom®, MassARRAY®, EpiTYPER™, and iPLEX™ are trademarks of Sequenom, Inc.

Contact Information: Contacts: Vipin Adhlakha BioServe 301-470-3362 Email Contact Constantine Theodoropulos Boston Communications 617-619-9801 Email Contact